Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN AND DEXTROSE versus CEFOTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN AND DEXTROSE versus CEFOTAN.
CEFAZOLIN AND DEXTROSE vs CEFOTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal agent inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis. Dextrose provides osmotic diuresis and energy source.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, and activating autolytic enzymes.
1-2 g IV/IM every 8 hours; maximum 12 g/day.
1-2 g IV/IM every 12 hours for 5-10 days; up to 6 g/day for severe infections.
None Documented
None Documented
1.8 hours (prolonged to 20-40 hours in severe renal impairment, CrCl <10 mL/min)
Terminal elimination half-life: 4.5 hours (intravenous). In patients with renal impairment (CrCl <30 mL/min), half-life extends to approximately 20–30 hours, requiring dose adjustment.
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal (<5%)
Primarily renal (unchanged); ~88% excreted in urine within 24 hours. Biliary/fecal elimination is negligible (<1% as metabolites).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic